去纤苷（去纤维钠）的副作用

Hepatic veno-occlusive disease (VOD) is one of the serious complications after hematopoietic stem cell transplantation (HSCT), and the mortality rate in patients with severe VOD can be as high as 100%. Defibrotide is a mixture of single-stranded oligonucleotides that has anti-thrombotic and fibrinolytic effects. In recent years, multiple clinical research results have shown that defibrotide (defiteli) is a safe and effective drug for preventing and treating VOD after HSCT. So, what are the side effects of defibrotide (defiteli)? Let’s take a look at it together.

Defibrotide (Defibrotide Sodium, Defiteli) Dosing Guidelines: The recommended dose of Defibrotide (Defibrotide Sodium, defiteli) for adult and pediatric patients is 6.25 mg/kg given every 6 hours as a 2-hour intravenous infusion. The dose should be based on the patient's baseline weight, which is defined as the patient's weight before the HSCT preparation protocol. Defibrotide was administered for a minimum of 21 days. If signs and symptoms of hepatic VOD have not resolved after 21 days, continue defibrination until resolution of VOD or up to a maximum of 60 days. Defibrotide (defiteli) must be diluted before infusion.

Defiteli is well tolerated, and the most common side effects (incidence ≥10% and independent causal relationship) with treatment with defiteli are hypotension, diarrhea, vomiting, nausea, and epistaxis. The incidence of grade 3-4 reactions related to defibrotide was 7%, mainly hypotension, pulmonary and gastrointestinal bleeding, and abdominal cramps. Only 4% of patients discontinued treatment due to side effects. In other words, the side effects of defibrotide (defiteli) are usually mild.

Although the side effects are mild, patients must mainly eat a light diet and pay attention to balanced nutrition; maintain adequate sleep and enhance the body's resistance. If the patient feels that the side effects are strong and unbearable during the medication, he should stop taking the medication and seek medical treatment in time. If you have any other questions, please consult the medical companion passenger service.